You would be surprised to find out just how many questions are answered by the analysis of the relationship that emerges between generic competition and drug prices. For manufacturers and…
Valuing pharma companies isn’t the same as valuing non-pharma companies, for several reasons. Traditional business considerations are compounded by patent law and FDA approval processes when evaluating the investment potential of…